Changes to colorectal cancer screening discussed
Exact Sciences (Marlborough, Massachusetts), which uses applied genomics in an effort to develop patient-friendly screening technologies for use in the detection of cancer, reported that members of the American Cancer Society Colorectal Cancer Advisory Committee and members of a Multi-Society Task Force on Colorectal Cancer convened recently in Atlanta to discuss potential updates to current colon cancer screening guidelines.
During this meeting, the members discussed, among other topics, the potential inclusion of stool-based DNA testing among the current colon cancer screening guidelines recommendations. In advance of the meeting, Exact Sciences supplied the attendees with a variety of peer-reviewed articles, clinical evidence, economic analyses, and scientific research in support of stool-based DNA testing.
WorldHeart not in Nasdaq compliance
WorldHeart (Oakland, California), which focuses on mechanical circulatory support systems, reported that it received a notice from the Nasdaq that for the last 30 consecutive business days, the bid price of the company's common shares has closed below the minimum $1 per share requirement, and if it does not regain compliance by Dec. 18, it will be delisted.
If, at anytime before Dec. 18, the bid price of World Heart's common shares closes at $1 per share or more for a minimum of 10 consecutive business days, the company may regain compliance.
The Nasdaq staff may require the company to maintain a bid price of at least $1 per share for a period in excess of 10 consecutive business days (but generally no more than 20 consecutive business days) before determining that it has demonstrated the ability to maintain long-term compliance.
Vasomedical trading on OTCBB
Vasomedical (Westbury, New York), reported that it has received notification from the National Association of Securities Dealers that effective as of the open of business on June 20, the company's common stock is listed on the Over-the-Counter Bulletin Board (OTCBB) under the trading symbol VASO.OB.
Vasomedical makes EECP external counterpulsation systems based on the company's technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock.